 Kent Hutchison
Concepts (540)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 65 | 2023 | 764 | 10.900 |
Why?
| | Alcohol Drinking | 48 | 2024 | 751 | 7.510 |
Why?
| | Cues | 38 | 2018 | 321 | 5.240 |
Why?
| | Brain | 54 | 2024 | 2615 | 4.810 |
Why?
| | Ethanol | 31 | 2021 | 585 | 3.960 |
Why?
| | Cannabis | 20 | 2024 | 426 | 3.850 |
Why?
| | Alcohol-Related Disorders | 17 | 2021 | 118 | 3.800 |
Why?
| | Cannabidiol | 10 | 2024 | 89 | 3.510 |
Why?
| | Magnetic Resonance Imaging | 59 | 2024 | 3371 | 3.280 |
Why?
| | Tobacco Use Disorder | 15 | 2021 | 237 | 3.050 |
Why?
| | Smoking | 30 | 2019 | 1459 | 2.860 |
Why?
| | Marijuana Abuse | 16 | 2024 | 230 | 2.860 |
Why?
| | Cannabinoids | 8 | 2022 | 129 | 2.650 |
Why?
| | Substance-Related Disorders | 19 | 2023 | 1010 | 2.590 |
Why?
| | Dronabinol | 13 | 2024 | 167 | 2.440 |
Why?
| | Receptors, Dopamine D2 | 10 | 2018 | 89 | 2.350 |
Why?
| | Behavior, Addictive | 14 | 2021 | 81 | 2.280 |
Why?
| | Gray Matter | 7 | 2023 | 82 | 2.140 |
Why?
| | Adult | 134 | 2024 | 35177 | 2.020 |
Why?
| | Nerve Net | 10 | 2023 | 256 | 1.980 |
Why?
| | Reward | 11 | 2018 | 237 | 1.830 |
Why?
| | Brain Mapping | 14 | 2023 | 572 | 1.800 |
Why?
| | Varenicline | 4 | 2017 | 26 | 1.790 |
Why?
| | Polymorphism, Genetic | 14 | 2012 | 638 | 1.760 |
Why?
| | Marijuana Smoking | 7 | 2021 | 239 | 1.690 |
Why?
| | Neuroimaging | 9 | 2024 | 278 | 1.660 |
Why?
| | Receptors, Dopamine D4 | 11 | 2011 | 26 | 1.660 |
Why?
| | Male | 147 | 2024 | 62758 | 1.600 |
Why?
| | Naltrexone | 12 | 2019 | 84 | 1.580 |
Why?
| | Substance Withdrawal Syndrome | 13 | 2019 | 171 | 1.550 |
Why?
| | Genotype | 24 | 2014 | 1828 | 1.530 |
Why?
| | Executive Function | 5 | 2020 | 421 | 1.530 |
Why?
| | Female | 148 | 2024 | 68017 | 1.500 |
Why?
| | Flowers | 4 | 2024 | 58 | 1.480 |
Why?
| | White Matter | 3 | 2021 | 133 | 1.460 |
Why?
| | Mindfulness | 2 | 2023 | 114 | 1.430 |
Why?
| | Young Adult | 57 | 2024 | 12282 | 1.430 |
Why?
| | Humans | 194 | 2024 | 128020 | 1.390 |
Why?
| | Reflex, Startle | 9 | 2005 | 67 | 1.380 |
Why?
| | DNA Methylation | 9 | 2018 | 604 | 1.370 |
Why?
| | Alcoholic Intoxication | 5 | 2021 | 63 | 1.320 |
Why?
| | Central Nervous System Depressants | 10 | 2018 | 82 | 1.260 |
Why?
| | Gyrus Cinguli | 7 | 2017 | 79 | 1.200 |
Why?
| | Middle Aged | 68 | 2024 | 30813 | 1.190 |
Why?
| | Narcotic Antagonists | 9 | 2019 | 160 | 1.190 |
Why?
| | Polymorphism, Single Nucleotide | 27 | 2018 | 2059 | 1.170 |
Why?
| | Cigarette Smoking | 3 | 2018 | 87 | 1.170 |
Why?
| | Hallucinogens | 4 | 2022 | 86 | 1.160 |
Why?
| | Receptors, Opioid, mu | 6 | 2018 | 56 | 1.130 |
Why?
| | Affect | 14 | 2024 | 284 | 1.130 |
Why?
| | Taste | 5 | 2018 | 208 | 1.100 |
Why?
| | Receptor, Cannabinoid, CB1 | 5 | 2012 | 39 | 1.090 |
Why?
| | Smoking Cessation | 10 | 2017 | 407 | 1.080 |
Why?
| | Alcoholic Beverages | 3 | 2017 | 20 | 1.080 |
Why?
| | Motivation | 14 | 2015 | 544 | 1.060 |
Why?
| | Receptors, Nicotinic | 5 | 2014 | 323 | 1.050 |
Why?
| | Impulsive Behavior | 9 | 2017 | 128 | 1.050 |
Why?
| | Functional Neuroimaging | 9 | 2017 | 73 | 1.010 |
Why?
| | Toll-Like Receptor 4 | 2 | 2018 | 263 | 1.010 |
Why?
| | Nicotine | 12 | 2019 | 302 | 0.950 |
Why?
| | Amidohydrolases | 3 | 2009 | 30 | 0.940 |
Why?
| | Marijuana Use | 5 | 2020 | 189 | 0.940 |
Why?
| | Arousal | 6 | 2018 | 150 | 0.940 |
Why?
| | Nicotinic Agonists | 6 | 2017 | 125 | 0.930 |
Why?
| | Minisatellite Repeats | 9 | 2011 | 40 | 0.900 |
Why?
| | Taste Perception | 3 | 2015 | 23 | 0.880 |
Why?
| | Benzodiazepines | 6 | 2014 | 130 | 0.870 |
Why?
| | DNA Copy Number Variations | 4 | 2012 | 169 | 0.860 |
Why?
| | Medical Marijuana | 3 | 2021 | 106 | 0.840 |
Why?
| | Phenotype | 12 | 2015 | 3039 | 0.800 |
Why?
| | Cerebral Cortex | 9 | 2022 | 422 | 0.790 |
Why?
| | Risk-Taking | 5 | 2021 | 347 | 0.780 |
Why?
| | Parietal Lobe | 4 | 2014 | 48 | 0.740 |
Why?
| | Irritable Bowel Syndrome | 2 | 2019 | 28 | 0.730 |
Why?
| | Exercise | 8 | 2023 | 1917 | 0.700 |
Why?
| | Sensation Disorders | 1 | 2020 | 30 | 0.680 |
Why?
| | Antipsychotic Agents | 3 | 2014 | 192 | 0.660 |
Why?
| | Psychotherapy, Brief | 2 | 2011 | 31 | 0.660 |
Why?
| | Dopamine | 5 | 2013 | 285 | 0.650 |
Why?
| | Psychomotor Performance | 5 | 2013 | 311 | 0.650 |
Why?
| | Food | 3 | 2017 | 154 | 0.640 |
Why?
| | Adolescent | 42 | 2024 | 20158 | 0.640 |
Why?
| | Motor Activity | 3 | 2013 | 667 | 0.640 |
Why?
| | Genetic Variation | 5 | 2012 | 933 | 0.630 |
Why?
| | Models, Biological | 3 | 2015 | 1689 | 0.630 |
Why?
| | Genetic Predisposition to Disease | 6 | 2013 | 2261 | 0.620 |
Why?
| | Exons | 2 | 2011 | 338 | 0.620 |
Why?
| | Diffusion Tensor Imaging | 3 | 2015 | 73 | 0.610 |
Why?
| | Self Report | 6 | 2021 | 796 | 0.610 |
Why?
| | Stress, Psychological | 5 | 2012 | 1060 | 0.600 |
Why?
| | Plant Extracts | 1 | 2020 | 185 | 0.600 |
Why?
| | Double-Blind Method | 16 | 2024 | 1852 | 0.590 |
Why?
| | Severity of Illness Index | 8 | 2018 | 2703 | 0.580 |
Why?
| | Receptors, GABA-A | 2 | 2009 | 97 | 0.570 |
Why?
| | Gastrointestinal Tract | 1 | 2019 | 182 | 0.560 |
Why?
| | Decision Making | 4 | 2018 | 846 | 0.560 |
Why?
| | Drinking | 1 | 2017 | 39 | 0.550 |
Why?
| | Oxygen | 7 | 2013 | 899 | 0.550 |
Why?
| | Exploratory Behavior | 4 | 2009 | 86 | 0.540 |
Why?
| | Saliva | 3 | 2019 | 207 | 0.540 |
Why?
| | Sex Characteristics | 6 | 2021 | 719 | 0.530 |
Why?
| | Brain Injuries, Traumatic | 2 | 2021 | 337 | 0.530 |
Why?
| | Craving | 5 | 2023 | 40 | 0.520 |
Why?
| | Catechol O-Methyltransferase | 3 | 2011 | 18 | 0.520 |
Why?
| | Nerve Fibers, Myelinated | 2 | 2013 | 43 | 0.520 |
Why?
| | Corpus Striatum | 4 | 2017 | 155 | 0.510 |
Why?
| | Heart Rate | 9 | 2018 | 797 | 0.490 |
Why?
| | Cognitive Dysfunction | 1 | 2020 | 343 | 0.490 |
Why?
| | Gastrointestinal Microbiome | 2 | 2020 | 631 | 0.490 |
Why?
| | Coronary Disease | 1 | 2018 | 384 | 0.480 |
Why?
| | Drug Users | 1 | 2015 | 41 | 0.480 |
Why?
| | Brain-Derived Neurotrophic Factor | 6 | 2015 | 110 | 0.470 |
Why?
| | Anxiety | 3 | 2024 | 951 | 0.470 |
Why?
| | Interview, Psychological | 2 | 2011 | 88 | 0.460 |
Why?
| | Photic Stimulation | 5 | 2014 | 239 | 0.450 |
Why?
| | Prefrontal Cortex | 3 | 2014 | 299 | 0.450 |
Why?
| | Cerebrum | 1 | 2013 | 6 | 0.440 |
Why?
| | Treatment Outcome | 15 | 2017 | 10110 | 0.440 |
Why?
| | Retinal Dehydrogenase | 1 | 2013 | 30 | 0.440 |
Why?
| | Epigenesis, Genetic | 3 | 2013 | 614 | 0.440 |
Why?
| | Chronic Pain | 1 | 2018 | 253 | 0.430 |
Why?
| | Biomedical Research | 1 | 2019 | 632 | 0.420 |
Why?
| | Mental Disorders | 5 | 2022 | 1005 | 0.410 |
Why?
| | alpha-Synuclein | 1 | 2013 | 32 | 0.410 |
Why?
| | Body Weight | 1 | 2017 | 930 | 0.410 |
Why?
| | Receptors, Neurokinin-1 | 1 | 2012 | 12 | 0.410 |
Why?
| | Pirenzepine | 2 | 2003 | 7 | 0.400 |
Why?
| | Genome-Wide Association Study | 3 | 2016 | 1330 | 0.400 |
Why?
| | Models, Psychological | 6 | 2011 | 306 | 0.400 |
Why?
| | Aging | 4 | 2022 | 1745 | 0.390 |
Why?
| | Analysis of Variance | 12 | 2012 | 1266 | 0.390 |
Why?
| | Attention | 4 | 2020 | 433 | 0.390 |
Why?
| | Secondary Prevention | 2 | 2023 | 217 | 0.380 |
Why?
| | Mouth | 2 | 2024 | 80 | 0.380 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 2011 | 41 | 0.380 |
Why?
| | Dose-Response Relationship, Drug | 9 | 2015 | 1943 | 0.380 |
Why?
| | Personality | 2 | 2006 | 122 | 0.370 |
Why?
| | Receptor, Muscarinic M2 | 1 | 2011 | 9 | 0.370 |
Why?
| | Surveys and Questionnaires | 19 | 2013 | 5353 | 0.370 |
Why?
| | Cytidine Deaminase | 1 | 2011 | 57 | 0.370 |
Why?
| | Pharmacogenetics | 2 | 2010 | 171 | 0.360 |
Why?
| | Protons | 1 | 2011 | 80 | 0.360 |
Why?
| | Extinction, Psychological | 1 | 2012 | 86 | 0.360 |
Why?
| | Limbic System | 2 | 2008 | 46 | 0.350 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2011 | 100 | 0.340 |
Why?
| | Intelligence | 1 | 2011 | 129 | 0.340 |
Why?
| | Cytokines | 2 | 2018 | 1984 | 0.340 |
Why?
| | Gene Deletion | 1 | 2011 | 369 | 0.330 |
Why?
| | Alleles | 6 | 2011 | 842 | 0.330 |
Why?
| | Students | 3 | 2011 | 570 | 0.330 |
Why?
| | Gene Expression | 3 | 2010 | 1454 | 0.330 |
Why?
| | Text Messaging | 1 | 2012 | 149 | 0.330 |
Why?
| | Choice Behavior | 1 | 2011 | 164 | 0.330 |
Why?
| | Genomics | 2 | 2012 | 714 | 0.320 |
Why?
| | Personality Inventory | 5 | 2011 | 137 | 0.320 |
Why?
| | Connectome | 3 | 2024 | 84 | 0.320 |
Why?
| | Proteins | 2 | 2013 | 933 | 0.320 |
Why?
| | Diabetes Mellitus | 1 | 2018 | 994 | 0.320 |
Why?
| | Psychotherapy, Group | 1 | 2009 | 64 | 0.320 |
Why?
| | Avoidance Learning | 1 | 2009 | 67 | 0.310 |
Why?
| | Genetic Linkage | 1 | 2009 | 299 | 0.300 |
Why?
| | Depression | 2 | 2024 | 1290 | 0.300 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2007 | 6 | 0.290 |
Why?
| | Breath Tests | 5 | 2009 | 89 | 0.290 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2024 | 1356 | 0.290 |
Why?
| | Obesity | 2 | 2018 | 2859 | 0.280 |
Why?
| | Image Processing, Computer-Assisted | 8 | 2016 | 734 | 0.280 |
Why?
| | Counseling | 1 | 2011 | 382 | 0.280 |
Why?
| | Methylation | 2 | 2018 | 227 | 0.280 |
Why?
| | Alcohols | 1 | 2007 | 28 | 0.280 |
Why?
| | Infusions, Intravenous | 4 | 2018 | 390 | 0.280 |
Why?
| | Drug Resistance | 1 | 2007 | 165 | 0.270 |
Why?
| | Acoustic Stimulation | 3 | 2013 | 325 | 0.270 |
Why?
| | Health Education | 1 | 2009 | 332 | 0.260 |
Why?
| | Hydrocortisone | 1 | 2008 | 304 | 0.260 |
Why?
| | Case-Control Studies | 10 | 2017 | 3324 | 0.260 |
Why?
| | Sex Factors | 8 | 2021 | 1942 | 0.250 |
Why?
| | Microbiota | 3 | 2024 | 719 | 0.250 |
Why?
| | Organ Size | 5 | 2018 | 440 | 0.250 |
Why?
| | Physical Fitness | 2 | 2020 | 203 | 0.250 |
Why?
| | Diagnostic Imaging | 1 | 2008 | 329 | 0.240 |
Why?
| | Homosexuality, Female | 1 | 2005 | 39 | 0.240 |
Why?
| | Self Concept | 1 | 2007 | 241 | 0.240 |
Why?
| | Program Evaluation | 1 | 2009 | 872 | 0.240 |
Why?
| | Body Mass Index | 4 | 2020 | 2260 | 0.240 |
Why?
| | Genetic Association Studies | 5 | 2015 | 361 | 0.240 |
Why?
| | Helplessness, Learned | 1 | 2005 | 62 | 0.240 |
Why?
| | Adolescent Behavior | 3 | 2021 | 505 | 0.240 |
Why?
| | CpG Islands | 2 | 2016 | 151 | 0.230 |
Why?
| | Patient-Centered Care | 1 | 2010 | 493 | 0.230 |
Why?
| | Depressive Disorder, Major | 2 | 2024 | 344 | 0.230 |
Why?
| | Social Perception | 1 | 2005 | 104 | 0.230 |
Why?
| | Homosexuality, Male | 1 | 2005 | 175 | 0.220 |
Why?
| | Genome, Human | 3 | 2012 | 390 | 0.220 |
Why?
| | Tobacco Use | 1 | 2024 | 61 | 0.220 |
Why?
| | Anti-Anxiety Agents | 1 | 2024 | 42 | 0.220 |
Why?
| | Dopamine Uptake Inhibitors | 2 | 2003 | 55 | 0.210 |
Why?
| | Aspartic Acid | 3 | 2012 | 78 | 0.210 |
Why?
| | Alcohol Abstinence | 2 | 2014 | 12 | 0.210 |
Why?
| | Cognition | 3 | 2011 | 1104 | 0.200 |
Why?
| | Cross-Over Studies | 2 | 2023 | 507 | 0.200 |
Why?
| | Habituation, Psychophysiologic | 1 | 2003 | 53 | 0.200 |
Why?
| | Chi-Square Distribution | 4 | 2012 | 511 | 0.200 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2022 | 47 | 0.200 |
Why?
| | Sequence Analysis, DNA | 2 | 2020 | 771 | 0.200 |
Why?
| | Phosphocreatine | 2 | 2012 | 40 | 0.200 |
Why?
| | Central Nervous System Stimulants | 2 | 2004 | 153 | 0.200 |
Why?
| | Psychotic Disorders | 1 | 2024 | 151 | 0.200 |
Why?
| | Creatine | 2 | 2012 | 55 | 0.190 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2024 | 519 | 0.190 |
Why?
| | Individuality | 5 | 2011 | 155 | 0.190 |
Why?
| | Homozygote | 2 | 2012 | 192 | 0.190 |
Why?
| | Cannabinoid Receptor Agonists | 1 | 2021 | 36 | 0.190 |
Why?
| | Blood Pressure | 5 | 2018 | 1711 | 0.190 |
Why?
| | Harm Reduction | 1 | 2021 | 31 | 0.180 |
Why?
| | Hippocampus | 3 | 2021 | 801 | 0.180 |
Why?
| | Psychiatric Status Rating Scales | 4 | 2011 | 520 | 0.180 |
Why?
| | Endocannabinoids | 1 | 2021 | 39 | 0.180 |
Why?
| | Frontal Lobe | 2 | 2013 | 153 | 0.180 |
Why?
| | Axons | 2 | 2013 | 188 | 0.180 |
Why?
| | Cerebellar Cortex | 1 | 2021 | 21 | 0.180 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2131 | 0.170 |
Why?
| | Colorado | 4 | 2021 | 4369 | 0.170 |
Why?
| | Promoter Regions, Genetic | 2 | 2018 | 1198 | 0.170 |
Why?
| | Glutamic Acid | 2 | 2012 | 228 | 0.170 |
Why?
| | Verbal Learning | 1 | 2020 | 64 | 0.170 |
Why?
| | Dextroamphetamine | 1 | 1999 | 2 | 0.170 |
Why?
| | Schizophrenia | 1 | 2024 | 428 | 0.170 |
Why?
| | Support Vector Machine | 2 | 2018 | 36 | 0.170 |
Why?
| | Alcohol Deterrents | 2 | 2018 | 17 | 0.170 |
Why?
| | DNA Mutational Analysis | 3 | 2012 | 384 | 0.170 |
Why?
| | Dopamine and cAMP-Regulated Phosphoprotein 32 | 2 | 2011 | 9 | 0.160 |
Why?
| | Drug and Narcotic Control | 1 | 2019 | 28 | 0.160 |
Why?
| | Sexual Behavior | 2 | 2021 | 481 | 0.160 |
Why?
| | Knowledge | 1 | 2019 | 51 | 0.160 |
Why?
| | Comorbidity | 2 | 2018 | 1537 | 0.160 |
Why?
| | Brain Chemistry | 2 | 2011 | 115 | 0.160 |
Why?
| | Health Behavior | 3 | 2013 | 740 | 0.160 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 488 | 0.160 |
Why?
| | Sympathomimetics | 1 | 1999 | 23 | 0.160 |
Why?
| | Amphetamine | 1 | 1999 | 22 | 0.160 |
Why?
| | Risk Reduction Behavior | 1 | 2021 | 208 | 0.160 |
Why?
| | Cross-Sectional Studies | 5 | 2017 | 5034 | 0.160 |
Why?
| | Juvenile Delinquency | 2 | 2013 | 109 | 0.160 |
Why?
| | Neuropsychological Tests | 6 | 2018 | 1001 | 0.150 |
Why?
| | Cocaine-Related Disorders | 2 | 2018 | 108 | 0.150 |
Why?
| | Pain | 1 | 2024 | 748 | 0.150 |
Why?
| | Underage Drinking | 1 | 2018 | 20 | 0.150 |
Why?
| | Environment | 2 | 2010 | 342 | 0.150 |
Why?
| | Mass Spectrometry | 1 | 2021 | 662 | 0.140 |
Why?
| | Postural Balance | 1 | 2020 | 197 | 0.140 |
Why?
| | Pilot Projects | 5 | 2019 | 1559 | 0.140 |
Why?
| | Dysbiosis | 1 | 2019 | 166 | 0.140 |
Why?
| | Research Design | 3 | 2019 | 1034 | 0.140 |
Why?
| | Speech | 2 | 2012 | 74 | 0.140 |
Why?
| | Tobacco Smoking | 1 | 2017 | 25 | 0.140 |
Why?
| | Benzazepines | 1 | 2017 | 40 | 0.140 |
Why?
| | Information Dissemination | 1 | 2019 | 203 | 0.140 |
Why?
| | Southwestern United States | 1 | 2017 | 91 | 0.140 |
Why?
| | Biomarkers | 3 | 2021 | 3874 | 0.140 |
Why?
| | Placebo Effect | 1 | 2017 | 55 | 0.140 |
Why?
| | Gene Frequency | 3 | 2008 | 504 | 0.140 |
Why?
| | Beverages | 1 | 2017 | 67 | 0.130 |
Why?
| | Interleukin-8 | 1 | 2018 | 258 | 0.130 |
Why?
| | Amygdala | 2 | 2021 | 186 | 0.130 |
Why?
| | Food Preferences | 1 | 2017 | 112 | 0.130 |
Why?
| | Exercise Therapy | 1 | 2020 | 412 | 0.130 |
Why?
| | Reaction Time | 2 | 2011 | 406 | 0.130 |
Why?
| | Hypnotics and Sedatives | 2 | 2009 | 156 | 0.130 |
Why?
| | Age Factors | 2 | 2013 | 3100 | 0.120 |
Why?
| | Interleukin-1beta | 1 | 2018 | 368 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2013 | 4853 | 0.120 |
Why?
| | Behavior | 2 | 2009 | 91 | 0.120 |
Why?
| | Proton Magnetic Resonance Spectroscopy | 1 | 2015 | 21 | 0.120 |
Why?
| | Placebos | 3 | 2007 | 201 | 0.120 |
Why?
| | Public Policy | 1 | 2015 | 67 | 0.120 |
Why?
| | Animals | 8 | 2019 | 34487 | 0.120 |
Why?
| | Radiography | 2 | 2015 | 794 | 0.120 |
Why?
| | Models, Neurological | 2 | 2015 | 236 | 0.120 |
Why?
| | Signal Transduction | 3 | 2019 | 4812 | 0.110 |
Why?
| | Legislation, Drug | 1 | 2015 | 76 | 0.110 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 141 | 0.110 |
Why?
| | Energy Intake | 1 | 2017 | 454 | 0.110 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 2 | 2012 | 74 | 0.110 |
Why?
| | United States | 6 | 2019 | 13785 | 0.110 |
Why?
| | Drug Interactions | 2 | 2007 | 361 | 0.110 |
Why?
| | Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2013 | 23 | 0.110 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 419 | 0.110 |
Why?
| | Interleukin-6 | 1 | 2018 | 712 | 0.110 |
Why?
| | Bacteria | 1 | 2020 | 812 | 0.110 |
Why?
| | Adaptation, Psychological | 2 | 2011 | 616 | 0.110 |
Why?
| | Nerve Tissue Proteins | 2 | 2010 | 569 | 0.110 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2013 | 27 | 0.100 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2017 | 395 | 0.100 |
Why?
| | Basal Ganglia | 1 | 2013 | 53 | 0.100 |
Why?
| | Sample Size | 1 | 2013 | 115 | 0.100 |
Why?
| | Factor Analysis, Statistical | 2 | 2015 | 283 | 0.100 |
Why?
| | Nucleus Accumbens | 2 | 2021 | 126 | 0.100 |
Why?
| | Stress Disorders, Traumatic | 1 | 2013 | 23 | 0.100 |
Why?
| | Nerve Fibers, Unmyelinated | 1 | 2012 | 9 | 0.100 |
Why?
| | Hypothalamo-Hypophyseal System | 2 | 2008 | 177 | 0.100 |
Why?
| | Body Temperature | 1 | 2013 | 212 | 0.100 |
Why?
| | Models, Genetic | 2 | 2007 | 591 | 0.100 |
Why?
| | Norepinephrine | 1 | 2013 | 209 | 0.100 |
Why?
| | Receptors, Serotonin | 1 | 2012 | 33 | 0.100 |
Why?
| | Mental Health | 1 | 2019 | 683 | 0.100 |
Why?
| | Reproducibility of Results | 4 | 2023 | 3009 | 0.100 |
Why?
| | Auditory Perception | 1 | 2013 | 111 | 0.100 |
Why?
| | Predictive Value of Tests | 2 | 2012 | 1934 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2014 | 2706 | 0.100 |
Why?
| | Glutamine | 1 | 2012 | 94 | 0.100 |
Why?
| | Cerebrospinal Fluid | 1 | 2012 | 89 | 0.100 |
Why?
| | Lactic Acid | 1 | 2013 | 294 | 0.100 |
Why?
| | Life Style | 2 | 2012 | 459 | 0.100 |
Why?
| | Visual Perception | 1 | 2013 | 162 | 0.100 |
Why?
| | Glycerylphosphorylcholine | 1 | 2011 | 6 | 0.100 |
Why?
| | Heterozygote | 1 | 2012 | 267 | 0.090 |
Why?
| | Inositol | 1 | 2011 | 26 | 0.090 |
Why?
| | Phosphorylcholine | 1 | 2011 | 18 | 0.090 |
Why?
| | Choline | 1 | 2012 | 119 | 0.090 |
Why?
| | Gene-Environment Interaction | 1 | 2013 | 185 | 0.090 |
Why?
| | Prognosis | 2 | 2017 | 3766 | 0.090 |
Why?
| | Linear Models | 2 | 2016 | 816 | 0.090 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2011 | 46 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 1996 | 487 | 0.090 |
Why?
| | Neuroanatomy | 2 | 2021 | 9 | 0.090 |
Why?
| | Aldehyde Dehydrogenase, Mitochondrial | 1 | 2011 | 23 | 0.090 |
Why?
| | Association | 1 | 2011 | 12 | 0.090 |
Why?
| | Carbon Monoxide | 3 | 2007 | 68 | 0.090 |
Why?
| | Genetic Markers | 1 | 2012 | 338 | 0.090 |
Why?
| | Risk | 2 | 2011 | 850 | 0.090 |
Why?
| | Motivational Interviewing | 1 | 2012 | 100 | 0.090 |
Why?
| | Washington | 1 | 2011 | 148 | 0.090 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2010 | 157 | 0.090 |
Why?
| | Administration, Cutaneous | 2 | 2007 | 121 | 0.090 |
Why?
| | Brain Diseases | 1 | 2011 | 136 | 0.090 |
Why?
| | Pregnanolone | 1 | 2010 | 27 | 0.090 |
Why?
| | Genetic Testing | 2 | 2015 | 428 | 0.080 |
Why?
| | Euphoria | 1 | 2009 | 3 | 0.080 |
Why?
| | New Mexico | 1 | 2009 | 59 | 0.080 |
Why?
| | Oxygen Consumption | 1 | 2013 | 669 | 0.080 |
Why?
| | Professional-Patient Relations | 1 | 2011 | 139 | 0.080 |
Why?
| | Temperance | 1 | 2009 | 13 | 0.080 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2011 | 510 | 0.080 |
Why?
| | Smoking Prevention | 2 | 2007 | 161 | 0.080 |
Why?
| | Drug Design | 1 | 2010 | 155 | 0.080 |
Why?
| | Social Class | 1 | 2011 | 258 | 0.080 |
Why?
| | Presynaptic Terminals | 1 | 2009 | 68 | 0.080 |
Why?
| | Methamphetamine | 2 | 2019 | 54 | 0.080 |
Why?
| | Life Change Events | 2 | 2010 | 147 | 0.080 |
Why?
| | Brain Concussion | 1 | 2016 | 544 | 0.080 |
Why?
| | Probability | 1 | 2009 | 304 | 0.070 |
Why?
| | Opioid-Related Disorders | 1 | 2015 | 480 | 0.070 |
Why?
| | Time Factors | 4 | 2006 | 6479 | 0.070 |
Why?
| | Prospective Studies | 3 | 2013 | 7035 | 0.070 |
Why?
| | Risk Factors | 4 | 2013 | 9696 | 0.070 |
Why?
| | Genetics, Behavioral | 1 | 2007 | 40 | 0.070 |
Why?
| | Gambling | 1 | 2007 | 31 | 0.070 |
Why?
| | DNA Primers | 1 | 2008 | 509 | 0.070 |
Why?
| | Disruptive, Impulse Control, and Conduct Disorders | 1 | 2007 | 10 | 0.070 |
Why?
| | Neostriatum | 1 | 2007 | 34 | 0.070 |
Why?
| | Universities | 1 | 2009 | 399 | 0.070 |
Why?
| | Inflammation | 1 | 2018 | 2646 | 0.070 |
Why?
| | Injections, Intravenous | 1 | 2007 | 197 | 0.070 |
Why?
| | Twins, Dizygotic | 1 | 2007 | 180 | 0.070 |
Why?
| | Electromyography | 2 | 2000 | 381 | 0.070 |
Why?
| | Drinking Behavior | 1 | 2006 | 10 | 0.070 |
Why?
| | Retrospective Studies | 2 | 2015 | 14404 | 0.070 |
Why?
| | Siblings | 1 | 2007 | 215 | 0.070 |
Why?
| | Physical Exertion | 2 | 2023 | 207 | 0.070 |
Why?
| | Synaptic Transmission | 1 | 2008 | 258 | 0.070 |
Why?
| | Twins, Monozygotic | 1 | 2007 | 209 | 0.070 |
Why?
| | Self Efficacy | 1 | 2009 | 371 | 0.060 |
Why?
| | Health Promotion | 1 | 2012 | 716 | 0.060 |
Why?
| | Sensation | 1 | 2006 | 50 | 0.060 |
Why?
| | Libido | 1 | 2005 | 24 | 0.060 |
Why?
| | Heterosexuality | 1 | 2005 | 43 | 0.060 |
Why?
| | Social Values | 1 | 2005 | 34 | 0.060 |
Why?
| | Patient Satisfaction | 1 | 2009 | 624 | 0.060 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2005 | 34 | 0.060 |
Why?
| | Synapses | 1 | 2009 | 383 | 0.060 |
Why?
| | Depressive Disorder | 1 | 2008 | 354 | 0.060 |
Why?
| | Bulimia | 1 | 2005 | 23 | 0.060 |
Why?
| | Stereotyping | 1 | 2005 | 46 | 0.060 |
Why?
| | DNA | 2 | 2010 | 1392 | 0.060 |
Why?
| | Binding Sites | 2 | 2007 | 1241 | 0.060 |
Why?
| | Internal-External Control | 1 | 2005 | 69 | 0.060 |
Why?
| | Appetite | 1 | 2005 | 56 | 0.060 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2005 | 67 | 0.060 |
Why?
| | Rain | 1 | 2005 | 45 | 0.060 |
Why?
| | Rivers | 1 | 2005 | 66 | 0.060 |
Why?
| | Cohort Studies | 3 | 2017 | 5378 | 0.060 |
Why?
| | Pregnancy | 2 | 1996 | 6355 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2009 | 733 | 0.060 |
Why?
| | Ganglionic Stimulants | 1 | 2003 | 12 | 0.060 |
Why?
| | Problem Solving | 1 | 2005 | 153 | 0.060 |
Why?
| | Disasters | 1 | 2005 | 91 | 0.060 |
Why?
| | Cyproheptadine | 1 | 2003 | 6 | 0.050 |
Why?
| | Pleasure | 1 | 2023 | 20 | 0.050 |
Why?
| | Interpersonal Relations | 1 | 2007 | 388 | 0.050 |
Why?
| | Rest | 1 | 2024 | 120 | 0.050 |
Why?
| | Bupropion | 1 | 2003 | 40 | 0.050 |
Why?
| | Serotonin Antagonists | 1 | 2003 | 31 | 0.050 |
Why?
| | Multimodal Imaging | 1 | 2024 | 109 | 0.050 |
Why?
| | Neural Pathways | 2 | 2016 | 292 | 0.050 |
Why?
| | Algorithms | 2 | 2007 | 1609 | 0.050 |
Why?
| | Physical Stimulation | 1 | 2003 | 74 | 0.050 |
Why?
| | Anisotropy | 2 | 2013 | 70 | 0.050 |
Why?
| | Membrane Transport Proteins | 1 | 2004 | 148 | 0.050 |
Why?
| | Genetics, Population | 1 | 2004 | 200 | 0.050 |
Why?
| | Child Behavior | 1 | 2004 | 235 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2003 | 267 | 0.050 |
Why?
| | Emotions | 1 | 2007 | 535 | 0.050 |
Why?
| | Attitude to Health | 1 | 2005 | 431 | 0.050 |
Why?
| | Models, Theoretical | 1 | 2005 | 541 | 0.050 |
Why?
| | Atmospheric Pressure | 1 | 2021 | 15 | 0.050 |
Why?
| | Running | 1 | 2023 | 222 | 0.050 |
Why?
| | Limit of Detection | 1 | 2021 | 55 | 0.050 |
Why?
| | Cognitive Dissonance | 1 | 2001 | 4 | 0.050 |
Why?
| | Proof of Concept Study | 1 | 2021 | 65 | 0.040 |
Why?
| | Quality Control | 1 | 2021 | 156 | 0.040 |
Why?
| | Neurons | 1 | 2009 | 1445 | 0.040 |
Why?
| | Wechsler Scales | 2 | 2012 | 53 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2669 | 0.040 |
Why?
| | Boredom | 1 | 1999 | 1 | 0.040 |
Why?
| | DNA, Ribosomal | 1 | 2020 | 82 | 0.040 |
Why?
| | Personality Tests | 1 | 1999 | 15 | 0.040 |
Why?
| | Psychophysiology | 1 | 1999 | 16 | 0.040 |
Why?
| | Conditioning, Classical | 1 | 2000 | 99 | 0.040 |
Why?
| | Receptors, Purinergic | 2 | 1990 | 21 | 0.040 |
Why?
| | Autism Spectrum Disorder | 1 | 2024 | 385 | 0.040 |
Why?
| | Thalamus | 2 | 2012 | 84 | 0.040 |
Why?
| | Quality Indicators, Health Care | 1 | 2021 | 296 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2020 | 323 | 0.040 |
Why?
| | Amphetamine-Related Disorders | 1 | 2018 | 36 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2007 | 2508 | 0.040 |
Why?
| | Blinking | 1 | 1997 | 8 | 0.040 |
Why?
| | Electroencephalography | 1 | 2000 | 396 | 0.040 |
Why?
| | Risk Assessment | 1 | 2007 | 3223 | 0.040 |
Why?
| | Pituitary-Adrenal System | 1 | 1999 | 144 | 0.040 |
Why?
| | Cocaine | 1 | 2019 | 148 | 0.040 |
Why?
| | Hyperkinesis | 1 | 2017 | 17 | 0.040 |
Why?
| | Self Administration | 1 | 2018 | 122 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2018 | 60 | 0.030 |
Why?
| | Association Learning | 1 | 2017 | 61 | 0.030 |
Why?
| | Central Nervous System Diseases | 1 | 1997 | 67 | 0.030 |
Why?
| | Aged | 4 | 2020 | 21892 | 0.030 |
Why?
| | Computer Simulation | 2 | 2015 | 936 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 1997 | 218 | 0.030 |
Why?
| | Volition | 1 | 1996 | 30 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 368 | 0.030 |
Why?
| | Sampling Studies | 1 | 1996 | 96 | 0.030 |
Why?
| | Self-Assessment | 1 | 1996 | 68 | 0.030 |
Why?
| | Maternal Behavior | 1 | 1996 | 74 | 0.030 |
Why?
| | Pregnancy Trimester, First | 1 | 1996 | 138 | 0.030 |
Why?
| | Hemodynamics | 1 | 2000 | 1077 | 0.030 |
Why?
| | Conduct Disorder | 1 | 2017 | 199 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2015 | 169 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1997 | 244 | 0.030 |
Why?
| | Athletic Performance | 1 | 2015 | 75 | 0.030 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2015 | 144 | 0.030 |
Why?
| | Salivation | 2 | 2007 | 4 | 0.030 |
Why?
| | Event-Related Potentials, P300 | 1 | 2013 | 14 | 0.030 |
Why?
| | Drug-Seeking Behavior | 1 | 2013 | 22 | 0.030 |
Why?
| | Data Interpretation, Statistical | 1 | 2015 | 335 | 0.030 |
Why?
| | Carrier Proteins | 2 | 2004 | 730 | 0.030 |
Why?
| | Placenta | 2 | 1990 | 716 | 0.030 |
Why?
| | Evoked Potentials | 1 | 2013 | 116 | 0.030 |
Why?
| | Chronic Disease | 1 | 1999 | 1690 | 0.030 |
Why?
| | Behavioral Symptoms | 1 | 2012 | 41 | 0.020 |
Why?
| | Research | 1 | 2015 | 408 | 0.020 |
Why?
| | Recurrence | 1 | 2015 | 993 | 0.020 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2012 | 56 | 0.020 |
Why?
| | Fornix, Brain | 1 | 2012 | 6 | 0.020 |
Why?
| | Spatial Analysis | 1 | 2012 | 21 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2013 | 477 | 0.020 |
Why?
| | Water | 1 | 2015 | 439 | 0.020 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2012 | 96 | 0.020 |
Why?
| | Functional Laterality | 1 | 2012 | 218 | 0.020 |
Why?
| | Haplotypes | 1 | 2013 | 471 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2012 | 315 | 0.020 |
Why?
| | Luciferases | 1 | 2010 | 147 | 0.020 |
Why?
| | Cerebellum | 1 | 2012 | 217 | 0.020 |
Why?
| | Methods | 1 | 2010 | 64 | 0.020 |
Why?
| | Chromosomes, Human, X | 1 | 2010 | 72 | 0.020 |
Why?
| | Chromosomes | 1 | 2010 | 101 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 354 | 0.020 |
Why?
| | Principal Component Analysis | 1 | 2010 | 182 | 0.020 |
Why?
| | Diagnosis, Dual (Psychiatry) | 1 | 2009 | 36 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 280 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 940 | 0.020 |
Why?
| | Transfection | 1 | 2010 | 891 | 0.020 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2009 | 236 | 0.020 |
Why?
| | Feedback, Psychological | 1 | 2007 | 21 | 0.020 |
Why?
| | Beer | 1 | 2007 | 7 | 0.020 |
Why?
| | Chewing Gum | 1 | 2007 | 9 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 7029 | 0.020 |
Why?
| | Tablets | 1 | 2007 | 35 | 0.020 |
Why?
| | Capsules | 1 | 2007 | 38 | 0.020 |
Why?
| | Learning | 1 | 2011 | 393 | 0.020 |
Why?
| | Blood Platelets | 1 | 1990 | 376 | 0.020 |
Why?
| | Child | 2 | 2022 | 20636 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2010 | 1492 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2010 | 1211 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2012 | 756 | 0.020 |
Why?
| | Demography | 1 | 2007 | 278 | 0.020 |
Why?
| | Body Temperature Regulation | 1 | 2007 | 95 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2007 | 303 | 0.020 |
Why?
| | Radar | 1 | 2005 | 1 | 0.020 |
Why?
| | Cerebrovascular Circulation | 1 | 2007 | 216 | 0.020 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2007 | 253 | 0.020 |
Why?
| | Geographic Information Systems | 1 | 2005 | 40 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2009 | 500 | 0.010 |
Why?
| | Psychometrics | 1 | 2009 | 679 | 0.010 |
Why?
| | Geography | 1 | 2005 | 186 | 0.010 |
Why?
| | Texas | 1 | 2005 | 227 | 0.010 |
Why?
| | Administration, Oral | 1 | 2007 | 766 | 0.010 |
Why?
| | Patient Compliance | 1 | 2008 | 558 | 0.010 |
Why?
| | Age Distribution | 1 | 2004 | 369 | 0.010 |
Why?
| | Sex Distribution | 1 | 2004 | 356 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2010 | 4006 | 0.010 |
Why?
| | Speech Production Measurement | 1 | 2002 | 12 | 0.010 |
Why?
| | Parent-Child Relations | 1 | 2004 | 256 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2004 | 467 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2010 | 3936 | 0.010 |
Why?
| | Societies, Medical | 1 | 2004 | 741 | 0.010 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 2 | 1990 | 10 | 0.010 |
Why?
| | Databases, Factual | 1 | 2005 | 1264 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2005 | 618 | 0.010 |
Why?
| | Prevalence | 1 | 2004 | 2541 | 0.010 |
Why?
| | Adenosine | 2 | 1990 | 212 | 0.010 |
Why?
| | Immune System | 1 | 1997 | 176 | 0.010 |
Why?
| | Cell Membrane | 2 | 1990 | 725 | 0.010 |
Why?
| | Radioligand Assay | 1 | 1990 | 47 | 0.010 |
Why?
| | Tritium | 1 | 1990 | 75 | 0.010 |
Why?
| | 2-Chloroadenosine | 1 | 1989 | 3 | 0.000 |
Why?
| | Guanylyl Imidodiphosphate | 1 | 1989 | 5 | 0.000 |
Why?
| | Guanine Nucleotides | 1 | 1989 | 15 | 0.000 |
Why?
| | Vasodilator Agents | 1 | 1990 | 323 | 0.000 |
Why?
| | Kinetics | 1 | 1989 | 1617 | 0.000 |
Why?
|
|
Hutchison's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|